副腎腫瘍に対する鏡視下副腎摘除術の検討　到達法別の治療成績の比較検討
大西 怜, 東島 克佳, 岩隈 景子, 守屋 良介, 湊 晶規, 富崎 一向, 藤本 直浩
Japanese Journal of Endourology, Apr. 2020, Reviewed, No invitation

ソフト凝固を用いた無阻血無縫合腹腔鏡下腎部分切除術における術後腎機能の検討
宮崎 一向, 大西 怜, 湊 晶規, 濱砂 良一, 藤本 直浩
Japanese Journal of Endourology, Apr. 2019, Reviewed, No invitation
Lead

非典型的な主訴で来院した梅毒の2例
呉竹景介、舟越恵太、野間悠太朗、谷川堅太郎、大野大地、松川卓生、高場智久、城嶋和真、原田みりい、木室里依子、東島克佳、永田祐二郎、湊 晶規、富崎一向、原田健一、藤本直浩、岡田悦子
日本性感染症学会誌, Sep. 2023, Reviewed, No invitation

非典型的な主訴で来院した梅毒の2例
呉竹 景介, 舟越 恵太, 野間 悠太朗, 谷川 堅太郎, 大野 大地, 松川 卓生, 高場 智久, 城嶋 和真, 原田 みりい, 木室 里依子, 東島 克佳, 永田 祐二郎, 湊 晶規, 富崎 一向, 原田 健一, 藤本 直浩, 岡田 悦子
日本性感染症学会誌, Mar. 2024, Reviewed, No invitation

局所進行膀胱癌に対する膀胱全摘除術後補助化学療法の有効性
湊 晶規, 富崎 一向, 木室 里依子, 東島 克佳, 原田 みりい, 城嶋 和真, 坂本 卓郎, 高場 智久, 大野 大地, 呉竹 景介, 谷川 堅太郎, 松川 卓生, 原田 健一, 藤本 直浩
日本泌尿器科学会雑誌, Oct. 2023, Reviewed, No invitation

顆粒球コロニー刺激因子(G-CSF)産生浸潤性膀胱癌の1例　本邦報告例のまとめ
湊 晶規, 藤本 直浩, 富崎 一向, 山崎 清玄, 中島 信能, 槇原 康亮
日本泌尿器科学会雑誌, Jul. 2018, Reviewed, No invitation

前立腺癌根治的放射線療法後のPSA再発に対する内分泌療法の奏効期間に関する検討
富崎一向, 藤本直浩, 寺戸三千和, 久保達彦, 松本哲朗
日本泌尿器科学会雑誌, Mar. 2013, Not reviewed, No invitation

前立腺癌に対するホルモン療法反応性の人種差におけるSLCO遺伝子多型の関与
藤本直浩, 久保達彦, HOAI Bui, 稲富久人, 富崎一向, 松本哲朗
日本泌尿器科学会雑誌, Mar. 2013, Not reviewed, No invitation

浸潤性膀胱癌に対する根治的膀胱全摘除術施行までに要した期間が予後に与える影響の検討
富崎一向, 久保達彦, 藤本直浩, 松本哲朗
日本泌尿器科学会雑誌, Mar. 2012, Not reviewed, No invitation

泌尿器科診療ガイドラインの普及とその効果に対する検討
富崎一向, 久保達彦, 藤本直浩, 松本哲朗
日本泌尿器科学会雑誌, Mar. 2011, Not reviewed, No invitation

前立腺癌に対する根治療法後の再発症例に対するIntermittent Androgen Suppression(IAS)の検討
富崎一向, 藤本直浩, 久保達彦, 松本哲朗
日本泌尿器科学会雑誌, Feb. 2010, Not reviewed, No invitation

前立腺癌に対するMAB療法施行患者に対する,MAB療法施行前後の検査値の比較
富崎一向, 藤本直浩, 久保達彦, 野村昌良, 松本哲朗
日本癌治療学会誌, Sep. 2009, Not reviewed, No invitation

PNLにおける術後有熱性尿路感染症発症の危険因子と術前抗菌薬治療による予防効果
松本 正広, 岩隈 景子, 守屋 良介, 生田 弘文, 大西 怜, 富崎 一向, 藤本 直浩
日本腎泌尿器疾患予防医学研究会誌, Mar. 2019, Not reviewed, No invitation

泌尿器科領域におけるトラブルシューティング(第93回)　泌尿器科手術における左右確認の重要性
原田 みりい, 富崎 一向, 藤本 直浩
泌尿器外科, Jul. 2018, Reviewed, Invited

去勢抵抗性前立腺癌に対して、間欠的にドセタキセルによる化学療法を施行した症例の治療成績
湊 晶規, 富崎 一向, 久保 達彦, 藤本 直浩
泌尿器外科, Aug. 2016, Not reviewed, Invited

【両立支援に欠かせない　産業保健スタッフに必要な疾患の知識と最新の治療法】(Part 2)出会う頻度の高い疾患の知識　膀胱がん・前立腺がん
富崎 一向, 藤本 直浩
産業保健と看護, Apr. 2020, Not reviewed, Invited
Lead

産業医科大学病院泌尿器科における2017年から2019年の臨床統計
室岡 和樹, 守屋 良介, 山崎 豪介, 岩隈 景子, 東島 克佳, 大西 怜, 湊 晶規, 松本 正広, 富崎 一向, 藤本 直浩
産業医科大学雑誌, Jun. 2022, Reviewed, No invitation

ミトタン+EDP療法を施行した進行副腎皮質癌
湊 晶規, 野口 紘嗣, 富崎 一向, 生田 弘文, 永田 祐二郎, 藤本 直浩
臨床泌尿器科, Sep. 2018, Reviewed, No invitation

eribulinが著効した後腹膜脱分化型脂肪肉腫の一例
水嶋 唯, 富崎 一向, 寺戸 三千和, 稲富 久人, 湊 晶規, 原田 健一, 藤本 直浩, 原田 佳和, 島尻 正平, 中山 敏幸
西日本泌尿器科, Jun. 2023, Reviewed, No invitation

尿道原発悪性リンパ腫の1例
杉田 佳弘, 原田 みりい, 山村 走平, 安田 幸平, 木室 里依子, 東島 克佳, 松本 正広, 湊 晶規, 富崎 一向, 島尻 正平, 藤本 直浩
西日本泌尿器科, Jun. 2022, Reviewed, No invitation

前立腺粘液腺癌の1例
安田 幸平, 湊 晶規, 木室 里依子, 岩隈 景子, 富崎 一向, 藤本 直浩
西日本泌尿器科, Apr. 2022, Reviewed, No invitation

Paclitaxelおよび放射線療法が著効した膀胱原発血管肉腫の1例
大野大地、富﨑一向、守屋良介、東島克佳、大西怜、湊晶規、寺戸三千和、稲富久人、松山篤二、島尻正平、藤本直浩
西日本泌尿器科, 2021, Reviewed, No invitation

SunitinibとVDC-IE療法が有効であった腎Ewing肉腫の1例
奥村 豊, 守屋 良介, 大西 怜, 湊 晶規, 松本 正広, 富崎 一向, 藤本 直浩, 津田 陽二郎
西日本泌尿器科, Dec. 2021, Reviewed, Null

ロボット支援腹腔鏡下膀胱全摘除術の初期症例における周術期成績の検討
富崎 一向, 大西 怜, 山村 走平, 木室 里依子, 生田 弘文, 湊 晶規, 藤本 直浩, 濱砂 良一
西日本泌尿器科, Feb. 2021, Reviewed, Null
Lead

前立腺癌に対するビカルタミド単剤投与中に認めた男性子宮内膜症の1例
岩隈 景子, 湊 晶規, 富崎 一向, 藤本 直浩, 寺戸 三千和, 稲富 久人, 秋葉 純
西日本泌尿器科, Dec. 2020, Reviewed, No invitation

腎静脈原発平滑筋腫の1例
守屋 良介, 岩隈 景子, 富崎 一向, 西井 久枝, 濱砂 良一, 藤本 直浩, 名和田 彩, 中山 敏幸
西日本泌尿器科, May 2018, Reviewed, No invitation

術前生検によって確定診断が困難であった陰茎乳房外浸潤性Paget病の1例
生田 弘文, 西井 久枝, 永田 祐二郎, 湊 晶規, 松本 正広, 富崎 一向, 濱砂 良一, 藤本 直浩, 木下 俊輔, 大栗 隆行, 興梠 征典, 松山 篤二
西日本泌尿器科, Oct. 2016, Reviewed, No invitation

超高齢者の泌尿器がん治療 追加発言　高齢者の浸潤性膀胱癌に対する少量CDDP併用放射線治療の検討
松本 博臣, 森山 貴弘, 富崎 一向, 寺戸 三千和, 藤本 直浩, 松本 哲朗
西日本泌尿器科, Jul. 2010, Null, Null

異時性両側精巣垂捻転症の1例
富崎 一向, 稲富 久人, 藤本 直浩, 松本 哲朗
西日本泌尿器科, Mar. 2010, Null, Null

前立腺癌に対するneo‐adjuvantMAB療法施行患者の,MAB療法施行前後の検査値の比較
富崎一向, 藤本直浩, 久保達彦, 松本博臣, 松本哲朗
西日本泌尿器科, Oct. 2009, Not reviewed, No invitation

Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy.
Minato Akinori, Furubayashi Nobuki, Tomoda Toshihisa, Masaoka Hiroyuki, Song Yoohyun, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Kuroiwa Kentaro, Seki Narihito, Tomisaki Ikko, Nakamura Motonobu, Harada Kenichi, Fujimoto Naohiro
Anticancer research, Aug. 2024, Reviewed, No invitation

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato Akinori, Kimuro Rieko, Ohno Daichi, Tanigawa Kentarou, Kuretake Keisuke, Matsukawa Takuo, Takaba Tomohisa, Jojima Kazumasa, Harada Mirii, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Reviewed, No invitation

Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.
Fujimoto Naohiro, Tsubonuma Yuto, Nagata Yujiro, Minato Akinori, Tomisaki Ikko, Harada Kenichi, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Reviewed, No invitation

Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Nagata Yujiro, Jojima Kazumasa, Matsukawa Takuo, Tomisaki Ikko, Fujimoto Naohiro
Anticancer research, Oct. 2023, Reviewed, No invitation

Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Nagata Yujiro, Matsukawa Takuo, Tomisaki Ikko, Fujimoto Naohiro
Anticancer research, Jan. 2023, Reviewed, No invitation

Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.
Tomisaki Ikko, Harada Mirii, Sakano Shigeru, Terado Michikazu, Hamasuna Ryoichi, Harada Shuji, Matsumoto Hiroomi, Akasaka Soichiro, Nagata Yujiro, Minato Akinori, Harada Ken-Ichi, Fujimoto Naohiro
Anticancer research, Jan. 2023, Reviewed, No invitation
Lead

Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
Fujimoto Naohiro, Minato Akinori, Igawa Tsukasa, Hiroshige Tasuku, Obara Wataru, Fukuda Atsushi, Nagata Yujiro, Mizushima Yui, Tomisaki Ikko, Harada Kenichi
Anticancer research, Jun. 2022, Reviewed, No invitation

Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
Tomisaki Ikko, Harada Mirii, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Higashijima Katsuyoshi, Harada Kenichi, Fujimoto Naohiro
Anticancer research, Mar. 2022, Reviewed, No invitation
Lead

Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
Nagata Yujiro, Matsukawa Takuo, Tomisaki Ikko, Fujimoto Naohiro
Anticancer research, Feb. 2022, Reviewed, No invitation

Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.
Minato Akinori, Noguchi Hirotsugu, Kimuro Rieko, Mirii Harada, Yujiro Nagata, Hasegawa Yoshitaka, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
Anticancer research, Jan. 2022, Reviewed, No invitation

Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
Fujimoto Naohiro, Harada Kenichi, Shiota Masaki, Tomisaki Ikko, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Harada Mirii, Fujisawa Masato
Anticancer research, Oct. 2021, Reviewed, No invitation

Evaluation of the extent of variant histology in urothelial carcinoma as a predictive_x000D_ marker of clinical outcomes after radical cystectomy.
Minato A, Noguchi H, Moriya R, Higashijima K, Yamasaki G, Kimuro R, Hasegawa Y, Tomisaki I, Fujimoto N.
Cancer Diagnosis Prognosis, Jul. 2021, Reviewed, No invitation

Oncological Outcome After Radical Prostatectomy Without Pelvic Lymph Node Dissection for Localized Prostate Cancer: Follow-up Results in a Single Institution.
Ikko Tomisaki , Hirofumi Ikuta , Katsuyoshi Higashijima , Rei Onishi , Akinori Minato , Naohiro Fujimoto
Cancer Investigation, Oct. 2019, Reviewed, No invitation
Lead

Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
Minato Akinori, Noguchi Hirotsugu, Tomisaki Ikko, Fukuda Atsushi, Kubo Tatsuhiko, Nakayama Toshiyuki, Fujimoto Naohiro
Cancer control : journal of the Moffitt Cancer Center, Sep. 2018, Reviewed, No invitation

Efficacy and Tolerability of Bacillus Calmette-Guérin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ.
Tomisaki Ikko, Kubo Tatsuhiko, Minato Akinori, Fujimoto Naohiro
Cancer investigation, Feb. 2018, Reviewed, No invitation
Lead

Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato Akinori, Furubayashi Nobuki, Tomoda Toshihisa, Masaoka Hiroyuki, Song Yoohyun, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Kuroiwa Kentaro, Seki Narihito, Tomisaki Ikko, Harada Kenichi, Nakamura Motonobu, Fujimoto Naohiro
Clinical genitourinary cancer, Oct. 2024, Reviewed, No invitation

Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato Akinori, Furubayashi Nobuki, Harada Mirii, Negishi Takahito, Sakamoto Naotaka, Song Yoohyun, Hori Yoshifumi, Tomoda Toshihisa, Tamura Shingo, Kuroiwa Kentaro, Seki Narihito, Tomisaki Ikko, Harada Kenichi, Nakamura Motonobu, Fujimoto Naohiro
Clinical genitourinary cancer, Oct. 2022, Reviewed, Null

Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer.
Fujimoto Naohiro, Shiota Masaki, Tomisaki Ikko, Minato Akinori
Clinical genitourinary cancer, Jan. 2017, Reviewed, No invitation

Cessation of Primary Androgen Deprivation Therapy for Men With Localized Prostate Cancer.
Fujimoto Naohiro, Kubo Tatsuhiko, Tomisaki Ikko
Clinical genitourinary cancer, Aug. 2015, Reviewed, No invitation
Last

Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma on Dialysis: A Case Report.
Tsubonuma Yuto, Nagata Yujiro, Higashijima Katsuyoshi, Minato Akinori, Tomisaki Ikko, Fujimoto Naohiro
Cureus, Jan. 2025, Reviewed, No invitation

Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Minato Akinori, Furubayashi Nobuki, Nagata Yujiro, Tomoda Toshihisa, Masaoka Hiroyuki, Song Yoohyun, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Kuroiwa Kentaro, Seki Narihito, Tomisaki Ikko, Harada Kenichi, Nakamura Motonobu, Fujimoto Naohiro
Current oncology (Toronto, Ont.), Feb. 2024, Reviewed, No invitation

中皮からの移行を伴う後腹膜原発粘液性嚢胞腺癌(Primary retroperitoneal mucinous cystadenocarcinoma with transition from the mesothelium)
Tomisaki Ikko, Matsuyama Atsuji, Jotatsu Mao, Yamamura Sohei, Onishi Rei, Fujimoto Naohiro
IJU Case Reports, Jul. 2020, Null, Null

中皮からの移行を伴う後腹膜原発粘液性嚢胞腺癌(Primary retroperitoneal mucinous cystadenocarcinoma with transition from the mesothelium)
Tomisaki Ikko, Matsuyama Atsuji, Jotatsu Mao, Yamamura Sohei, Onishi Rei, Fujimoto Naohiro
IJU Case Reports, Jul. 2020, Null, Null

「膀胱癌患者における筋炎および推定心筋炎を伴うペムブロリズマブ誘発性重症筋無力症」に対するエディトリアルコメント(Editorial Comment to Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer)
Tomisaki Ikko
IJU Case Reports, Jan. 2020, Null, Null

「膀胱癌患者における筋炎および推定心筋炎を伴うペムブロリズマブ誘発性重症筋無力症」に対するエディトリアルコメント(Editorial Comment to Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer)
Tomisaki Ikko
IJU Case Reports, Jan. 2020, Null, Null

Editorial Comment to Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer.
Ikko Tomisaki
IJU Case Reports, Dec. 2019, Reviewed, No invitation
Lead, Corresponding

Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor.
Harada Mirii, Tomisaki Ikko, Shimajiri Shohei, Kuretake Keisuke, Harada Kenichi, Fujimoto Naohiro
IJU case reports, Nov. 2023, Reviewed, No invitation

Editorial Comment to A conservative treatment for eosinophilic cystitis.
Tomisaki Ikko
IJU case reports, Jan. 2023, Null, Null
Lead

Editorial Comment to Tri-modality therapy with i-125 brachytherapy, external beam radiation therapy, and short-term hormone therapy for high-risk prostate cancer after holmium laser enucleation of the prostate.
Tomisaki Ikko
IJU case reports, Jul. 2022, Reviewed, No invitation
Lead

Three-month prostate-specific antigen level after androgen deprivation therapy predicts survival in patients with metastatic castration-sensitive prostate cancer.
Fujimoto N, Shiota M, Matsukawa T, Minato A, Tomisaki I, Ohnishi R, Eto M
In Vivo, Mar. 2021, Reviewed, No invitation

The Omission of Upfront Treatment Intensification Does Not Adversely Affect Oncological Outcomes in a Subset of Castration-Highly Sensitive Metastatic Prostate Cancer.
Fujimoto Naohiro, Nagata Yujiro, Shiota Masaki, Minato Akinori, Tomisaki Ikko, Harada Kenichi, Eto Masatoshi, Miyamoto Hiroshi
In vivo (Athens, Greece), 2024, Reviewed, No invitation

Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
Minato Akinori, Ohno Daichi, Murooka Kazuki, Okumura Yutaka, Takaba Tomohisa, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
In vivo (Athens, Greece), 2024, Reviewed, No invitation

Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.
Minato Akinori, Murooka Kazuki, Okumura Yutaka, Takaba Tomohisa, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
In vivo (Athens, Greece), 2024, Reviewed, No invitation

Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.
Tomisaki Ikko, Harada Mirii, Tokutsu Kei, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Matsumoto Masahiro, Fujimoto Naohiro
In vivo (Athens, Greece), Nov. 2021, Reviewed, No invitation
Lead

Reduced Expression Level of GPX2 in T1 Bladder Cancer and its Role in Early-phase Invasion of Bladder Cancer.
Minato Akinori, Noguchi Hirotsugu, Ohnishi Rei, Tomisaki Ikko, Nakayama Toshiyuki, Fujimoto Naohiro
In vivo (Athens, Greece), Apr. 2021, Reviewed, No invitation

Primary retroperitoneal mucinous cystadenocarcinoma with transition from the mesothelium.
Ikko Tomisaki , Atsuji Matsuyama , Mao Jotatsu , Sohei Yamamura , Rei Onishi , Naohiro Fujimoto
International Journal of Urology, Mar. 2020, Reviewed, No invitation
Lead

進行性尿路上皮癌患者における白金製剤ベースの化学療法後のパクリタキセル+ゲムシタビン併用療法(Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer)
Harada Mirii, Tomisaki Ikko, Minato Akinori, Onishi Rei, Terado Michikazu, Inatomi Hisato, Fujimoto Naohiro
International Journal of Urology, Sep. 2021, Null, Null

Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Nagata Yujiro, Minato Akinori, Aono Hisami, Kimuro Rieko, Higashijima Katsuyoshi, Tomisaki Ikko, Harada Kenichi, Miyamoto Hiroshi, Fujimoto Naohiro
International journal of molecular sciences, Sep. 2024, Reviewed, No invitation

Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
Tomisaki Ikko, Harada Mirii, Sakano Shigeru, Terado Michikazu, Hamasuna Ryoichi, Harada Shuji, Matsumoto Hiroomi, Akasaka Soichiro, Nagata Yujiro, Minato Akinori, Harada Ken-Ichi, Fujimoto Naohiro
International journal of urology : official journal of the Japanese Urological Association, Sep. 2023, Reviewed, No invitation
Lead

Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma.
Harada Ken-Ichi, Miyake Hideaki, Furukawa Junya, Fujimoto Naohiro, Fujisawa Masato
International journal of urology : official journal of the Japanese Urological Association, Aug. 2022, Reviewed, No invitation

Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Harada Mirii, Tomisaki Ikko, Minato Akinori, Onishi Rei, Terado Michikazu, Inatomi Hisato, Fujimoto Naohiro
International journal of urology : official journal of the Japanese Urological Association, Jul. 2021, Reviewed, No invitation

Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma.
Minato Akinori, Takaba Tomohisa, Sugita Yoshihiro, Kaneko Yuya, Hongyo Ryota, Tanaka Toshinobu, Bando Taro, Sugi Takaomi, Mizushima Yui, Matsukawa Takuo, Jojima Kazumasa, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Kashiwagi Eiji
Japanese journal of clinical oncology, Mar. 2025, Reviewed, No invitation

Treatment Outcomes of Second-Line Systemic Therapy for Neuroendocrine Prostate Cancer: A Report of Four Cases.
Tsubonuma Yuto, Funakoshi Keita, Takaba Tomohisa, Jyojima Kazumasa, Minato Akinori, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
Journal of UOEH, 2024, Reviewed, No invitation

An Effective Case for Chyluria by Retroperitoneoscopic Lymphatic Disconnection.
Tomisaki Ikko, Hamasuna Ryoichi, Fujimoto Naohiro
Journal of endourology case reports, Apr. 2016, Reviewed, No invitation
Lead

Premature mortality due to malignancies of the kidney and bladder in Japan, 1980-2010.
Pham Truong-Minh, Kubo Tatsuhiko, Fujino Yoshihisa, Fujimoto Naohiro, Tomisaki Ikko, Minato Akinori, Matsuda Shinya
Journal of epidemiology, Nov. 2018, Reviewed, No invitation

Analysis of fluoroquinolone-resistance using MIC determination and homology modelling of ParC of contemporary Mycoplasma genitalium strains.
Hamasuna Ryoichi, Hanzawa Hiroyuki, Moritomo Ayako, Matsumoto Masahiro, Aono Hisami, Tomisaki Ikko, Akasaka Takaaki, Fujimoto Naohiro, Jensen Jørgen Skov
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, Mar. 2022, Reviewed, No invitation

[IMPACT OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER].
Minato Akinori, Tomisaki Ikko, Kimuro Rieko, Higashijima Katsuyoshi, Harada Mirii, Jojima Kazumasa, Sakamoto Takuro, Takaba Tomohisa, Ohno Daichi, Kuretake Keisuke, Tanigawa Kentarou, Matsukawa Takuo, Harada Kenichi, Fujimoto Naohiro
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2023, Reviewed, No invitation

Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" Approach.
Harada Kenichi, Shiota Masaki, Minato Akinori, Matsumoto Masahiro, Tomisaki Ikko, Fujisawa Masato, Fujimoto Naohiro
OncoTargets and therapy, May 2021, Reviewed, No invitation

Clinical significance of early kinetics of C‑reactive protein in patients with advanced urothelial carcinoma treated with pembrolizumab: Flare response and baseline levels predict oncological outcomes.
Tomisaki Ikko, Harada Mirii, Sakano Shigeru, Terado Michikazu, Hamasuna Ryoichi, Harada Shuji, Matsumoto Hiroomi, Akasaka Soichiro, Nagata Yujiro, Minato Akinori, Harada Ken-Ichi, Fujimoto Naohiro
Oncology letters, Dec. 2024, Reviewed, No invitation
Lead

Effect of Early Postoperative Rehabilitation on Length of Hospital Stay after Robot-assisted Radical Prostatectomy.
Higuchi Shuto, Matsugaki Ryutaro, Tomisaki Ikko, Fushimi Kiyohide, Matsuda Shinya, Saeki Satoru
Progress in rehabilitation medicine, Aug. 2023, Reviewed, No invitation

Efficacy of avelumab maintenance therapy for advanced urothelial carcinoma with histologic subtype and divergent differentiation: a multicenter retrospective study conducted by the Uro-Oncology Group in Kyushu.
Minato Akinori, Furubayashi Nobuki, Tomoda Toshihisa, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Kuroiwa Kentaro, Tomisaki Ikko, Harada Kenichi, Nakamura Motonobu, Fujimoto Naohiro
Translational andrology and urology, Jul. 2024, Reviewed, No invitation

Reconsideration on Clinical Benefit pf Pelvic Lymph Node Dissection during Radical _x000D_ Prostatectomy for Clinically Localized Prostate Cancer.
Naohiro Fujimoto , Masaki Shiota , Ikko Tomisaki , Akinori Minato , Katsuya Yahara
Urologia Internationalis, Apr. 2019, Reviewed, No invitation

限局性前立腺癌の男性患者に関する初回アンドロゲン剥奪療法の終了　受け入れ可能なのか?(Cessation of primary androgen deprivation therapy for men with localized prostate cancer: Is it acceptable?)
Fujimoto Naohiro, Tomisaki Ikko, Minato Akinori, Fukuda Atsushi, Matsumoto Masahiro, Nishii Hisae, Hamasuna Ryoichi
日本泌尿器科学会総会, Apr. 2017, Null, Null

Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
Tomisaki Ikko, Harada Mirii, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Higashijima Katsuyoshi, Harada Kenichi, Fujimoto Naohiro
Anticancer research, Mar. 2022, Null, Null

Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
Nagata Yujiro, Matsukawa Takuo, Tomisaki Ikko, Fujimoto Naohiro
Anticancer research, Feb. 2022, Null, Null

Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.
Minato Akinori, Noguchi Hirotsugu, Kimuro Rieko, Mirii Harada, Yujiro Nagata, Hasegawa Yoshitaka, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
Anticancer research, Jan. 2022, Null, Null

Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
Fujimoto Naohiro, Harada Kenichi, Shiota Masaki, Tomisaki Ikko, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Harada Mirii, Fujisawa Masato
Anticancer research, Oct. 2021, Null, Null

Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
Minato Akinori, Noguchi Hirotsugu, Tomisaki Ikko, Fukuda Atsushi, Kubo Tatsuhiko, Nakayama Toshiyuki, Fujimoto Naohiro
Cancer control : journal of the Moffitt Cancer Center, Null, Null

Evaluation of the Extent of Variant Histology in Urothelial Carcinoma as a Predictive Marker of Clinical Outcomes After Radical Cystectomy.
Minato Akinori, Noguchi Hirotsugu, Moriya Ryosuke, Higashijima Katsuyoshi, Yamasaki Gosuke, Kimuro Rieko, Hasegawa Yoshitaka, Tomisaki Ikko, Fujimoto Naohiro
Cancer diagnosis & prognosis, 2021, Null, Null

Oncological Outcome After Radical Prostatectomy without Pelvic Lymph Node Dissection for Localized Prostate Cancer: Follow-up Results in a Single Institution.
Tomisaki Ikko, Ikuta Hirofumi, Higashijima Katsuyoshi, Onishi Rei, Minato Akinori, Fujimoto Naohiro
Cancer investigation, 2019, Null, Null

Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.
Minato Akinori, Fujimoto Naohiro, Kubo Tatsuhiko
Clinical genitourinary cancer, Dec. 2017, Null, Null

Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer.
Fujimoto Naohiro, Shiota Masaki, Tomisaki Ikko, Minato Akinori
Clinical genitourinary cancer, Jun. 2017, Null, Null

Cessation of Primary Androgen Deprivation Therapy for Men With Localized Prostate Cancer.
Fujimoto Naohiro, Kubo Tatsuhiko, Tomisaki Ikko
Clinical genitourinary cancer, Aug. 2015, Null, Null

Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.
Tomisaki Ikko, Harada Mirii, Tokutsu Kei, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Matsumoto Masahiro, Fujimoto Naohiro
In vivo (Athens, Greece), Null, Null

Reduced Expression Level of GPX2 in T1 Bladder Cancer and its Role in Early-phase Invasion of Bladder Cancer.
Minato Akinori, Noguchi Hirotsugu, Ohnishi Rei, Tomisaki Ikko, Nakayama Toshiyuki, Fujimoto Naohiro
In vivo (Athens, Greece), 2021, Null, Null

Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer.
Fujimoto Naohiro, Shiota Masaki, Matsukawa Takuo, Minato Akinori, Tomisaki Ikko, Ohnishi Rei, Eto Masatoshi
In vivo (Athens, Greece), Null, Null

Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Harada Mirii, Tomisaki Ikko, Minato Akinori, Onishi Rei, Terado Michikazu, Inatomi Hisato, Fujimoto Naohiro
International journal of urology : official journal of the Japanese Urological Association, Sep. 2021, Null, Null

[Healing in the intestinal anastomosis--comparison of the Albert-Lembert and Gambee methods].
Hirata K, Konishi T, Ueda Y, Kurosaki S, Tomisaki I, Nasu K, Mitsuhashi K, Miyauchi D, Yamaguchi M, Itoh H
Journal of UOEH, Mar. 2000, Null, Null

An Effective Case for Chyluria by Retroperitoneoscopic Lymphatic Disconnection.
Tomisaki Ikko, Hamasuna Ryoichi, Fujimoto Naohiro
Journal of endourology case reports, 2016, Null, Null

Premature mortality due to malignancies of the kidney and bladder in Japan, 1980-2010.
Pham Truong-Minh, Kubo Tatsuhiko, Fujino Yoshihisa, Fujimoto Naohiro, Tomisaki Ikko, Minato Akinori, Matsuda Shinya
Journal of epidemiology, Nov. 2018, Null, Null

Analysis of fluoroquinolone-resistance using MIC determination and homology modelling of ParC of contemporary Mycoplasma genitalium strains.
Hamasuna Ryoichi, Hanzawa Hiroyuki, Moritomo Ayako, Matsumoto Masahiro, Aono Hisami, Tomisaki Ikko, Akasaka Takaaki, Fujimoto Naohiro, Jensen Jørgen Skov
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, Mar. 2022, Null, Null

Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" Approach.
Harada Kenichi, Shiota Masaki, Minato Akinori, Matsumoto Masahiro, Tomisaki Ikko, Fujisawa Masato, Fujimoto Naohiro
OncoTargets and therapy, 2021, Null, Null

Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer.
Fujimoto Naohiro, Shiota Masaki, Tomisaki Ikko, Minato Akinori, Yahara Katsuya
Urologia internationalis, 2019, Null, Null

Psrt2　出会う頻度の高い疾患の知識_x000D_ 10　膀胱がん・前立腺がん
藤本　直浩、富﨑　一向, Contributor
メディカ出版, Apr. 2020